Výsledky vyhledávání - "R. J. Israel"

Repeat Rifaximin for Irritable Bowel Syndrome: No Clinically Significant Changes in Stool Microbial Antibiotic Sensitivity

Autor: Mark Pimentel, Brooks D. Cash, Anthony Lembo, R. A. Wolf, Philip Schoenfeld, R. J. Israel

Publikováno v: Digestive Diseases and Sciences

Background Rifaximin has demonstrated efficacy and safety for diarrhea-predominant irritable bowel syndrome (IBS-D). Aim To determine the rifaximin repeat treatment effect on fecal bacterial antibiotic susceptibility. Methods Patients with IBS in Tri

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5aeb14f1efb65892340c1ff62401e5c
http://europepmc.org/articles/PMC5561162

Zobrazit plný text záznamu

Low Dose Interferon Alfa-2B for the Induction of Remission of Hairy Cell Leukemia: A Multi-institutional Study of 49 Patients

Autor: C. S. Portlock, Mark J. Ratain, J. Chiavello, J. Thompson, Howard Ozer, Rosemarie Mick, R. J. Israel, A. Fefer, Harvey M. Golomb, E. M. Bonnem

Publikováno v: Leukemia & Lymphoma. 5:335-340

This multicenter study reports on 49 patients with hairy cell leukemia (HCL) who were treated subcutaneously with alfa-2b interferon (Intron A, Schering Corporation, Kenilworth, N.J.), three times a week at a reduced dosage of 200,000 units/m(2), one

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72b10d97cec5184f8c6c651843fa2d35
https://doi.org/10.3109/10428199109067626

Zobrazit plný text záznamu

Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin

Autor: P B, Chapman, D, Morrisey, K S, Panageas, L, Williams, J J, Lewis, R J, Israel, W B, Hamilton, P O, Livingston

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(12)

Immunization with GMK vaccine (G(M2) ganglioside conjugated to keyhole limpet hemocyanin mixed with QS-21 adjuvant) induces anti-G(M2) antibodies in close to 100% of patients. We found previously that anti-G(D2) antibodies could be induced in some pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::cc1119036ea4e2d0e34bcd6383ab50f9
https://pubmed.ncbi.nlm.nih.gov/11156217

Zobrazit plný text záznamu

Recombinant CD4-IgG2 in human immunodeficiency virus type 1-infected children: phase 1/2 study. The Pediatric AIDS Clinical Trials Group Protocol 351 Study Team

Autor: W T, Shearer, R J, Israel, S, Starr, C V, Fletcher, D, Wara, M, Rathore, J, Church, J, DeVille, T, Fenton, B, Graham, P, Samson, S, Staprans, J, McNamara, J, Moye, P J, Maddon, W C, Olson

Publikováno v: The Journal of infectious diseases. 182(6)

The use of recombinant CD4-IgG2 in pediatric human immunodeficiency virus type 1 (HIV-1) infection was evaluated by single and multidose intravenous infusions in 18 children in a phase 1/2 study. The study drug was well tolerated, and dose proportion

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::1fa44b70555575f32dd909dfa45647b1
https://pubmed.ncbi.nlm.nih.gov/11069253

Zobrazit plný text záznamu

Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study

Autor: P B, Chapman, D M, Morrissey, K S, Panageas, W B, Hamilton, C, Zhan, A N, Destro, L, Williams, R J, Israel, P O, Livingston

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 6(3)

In a previous randomized Phase III trial (P. O. Livingston et al, J. Clin. Oncol., 12: 1036-1044, 1994), we demonstrated that immunization with GM2 and bacille Calmette-Guerin reduced the risk of relapse in stage III melanoma patients who were free o

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::33317c15e7b3289853828d9f34269f94
https://pubmed.ncbi.nlm.nih.gov/10741710

Zobrazit plný text záznamu

Novel prime-boost combinations of PSMA-based vaccines for prostate cancer

Autor: R. J. Durso, G. P. Donovan, J. P. Gardner, William C. Olson, R. Arrigale, S. Jacques, R. J. Israel, N. Schülke, M. Maughan

Publikováno v: Journal of Clinical Oncology. 23:2572-2572

2572 Background and Methods The development of vaccination strategies targeted to tumor antigens holds great promise for cancer therapy. Prostate-specific membrane antigen (PSMA) is an attractive c...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cb633a4afa54a6cbd281c525ce2e82ec
https://doi.org/10.1200/jco.2005.23.16_suppl.2572

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání